Reported Reactions

Devices › Coronary drug-eluting stent

Device brand name · Drug eluting coronary stent delivery system

XIENCE Everolimus Eluting Coronary Stent System: medical device reports filed with FDA

294 reports name it, 2008–2026. Manufacturer given most often on reports: Abbott Vascular. Product code NIQ.

294
device reports naming the brand
0% of all MAUDE reports · about 17 a year
29
reports, 12 months to August 2026
33 in the 12 months before
6.1%
classified as malfunction
42.8% across the product code
32.7%
classified as death, as reported
96 reports · not verified by FDA

FDA's MAUDE database holds 294 reports that name the brand "XIENCE Everolimus Eluting Coronary Stent System" (drug eluting coronary stent delivery system), received between October 2008 and August 2026; the manufacturer given most often on reports is Abbott Vascular. Spellings of one product vary from report to report.

29 reports arrived in the 12 months to August 2026, down 12% from 33 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (61.2%), death (32.7%) and malfunction (6.1%); across all coronary drug-eluting stent reports (product code NIQ) death is recorded in 8.7% and malfunction in 42.8%. Event type is the reporter's classification of the report, not a verified outcome.

The device problems coded most often are patient-device incompatibility (4.1%), difficult or delayed activation (1.4%) and off-label use (1.4%). The patient problems coded most often are myocardial infarction, thrombosis/thrombus and stenosis. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Reports by month, five years

01020Sep 2021: 0Oct 2021: 2Nov 2021: 0Dec 2021: 02022Jan 2022: 0Feb 2022: 3Mar 2022: 2Apr 2022: 3May 2022: 1Jun 2022: 4Jul 2022: 15Aug 2022: 0Sep 2022: 5Oct 2022: 0Nov 2022: 1Dec 2022: 22023Jan 2023: 2Feb 2023: 2Mar 2023: 2Apr 2023: 1May 2023: 0Jun 2023: 0Jul 2023: 4Aug 2023: 6Sep 2023: 0Oct 2023: 2Nov 2023: 0Dec 2023: 12024Jan 2024: 2Feb 2024: 2Mar 2024: 0Apr 2024: 4May 2024: 13Jun 2024: 2Jul 2024: 2Aug 2024: 1Sep 2024: 1Oct 2024: 0Nov 2024: 0Dec 2024: 02025Jan 2025: 0Feb 2025: 3Mar 2025: 1Apr 2025: 0May 2025: 2Jun 2025: 1Jul 2025: 5Aug 2025: 20Sep 2025: 0Oct 2025: 7Nov 2025: 0Dec 2025: 12026Jan 2026: 3Feb 2026: 3Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 13Aug 2026: 2

Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.

By year received

032632008: 520082009: 1420092010: 720102020: 6320202021: 6120212022: 3620222023: 2020232024: 2720242025: 4020252026: 212026

Event type and report source

Event type, as classified on the report

Death32.7%96
Injury61.2%180
Malfunction6.1%18
Other0%0
Not given0%0

Who filed the report

Manufacturer report100%294
Voluntary report0%0
User facility report0%0
Distributor report0%0
Not given0%0

Grey bar: all 128,932 reports carrying product code NIQ. Event type is the filer's classification and is not verified by FDA.

Device problems coded

Device problem (FDA code)ReportsShareShare across product code
Patient-device incompatibilitythe device did not suit the patient124.1%0.2%
Difficult or delayed activation41.4%0.1%
Off-label use41.4%0.1%
Breakthe device broke31%3.1%
Device damaged by another device31%1.4%
Difficult to advance31%1.3%
Improper or incorrect procedure or method31%2.6%
Malposition of device31%0.2%
Material deformation31%10.7%
Difficult to removethe device was hard to remove20.7%6%
Dislodged20.7%1.7%
Failure to advance20.7%15.8%
Activation failure10.3%0.4%
Device dislodged or dislocated10.3%8.5%
Insufficient device problem information10.3%0.5%
Material separation10.3%0.7%
Migrationthe device moved from where it was placed10.3%0.1%
Source, detachment from10.3%0.1%

FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.

Patient problems coded

Patient problem (FDA code)ReportsShare
Myocardial infarctionheart attack13144.6%
Thrombosis/thrombus7023.8%
Stenosis5217.7%
Thrombosis4716%
Deaththe patient died; cause not stated by this term3812.9%
Stroke/cva3712.6%
Hemorrhage/blood loss/bleeding299.9%
Ischemia268.8%
Angina165.4%
Obstruction/occlusion144.8%
Therapy/non-surgical treatment, additional82.7%
Hypersensitivity/allergic reaction72.4%
Perforation of vessels72.4%
Vascular dissection72.4%
Cardiac arrestthe heart stopped62%

Patient problem codes are present mainly in reports filed since 2019 and are often blank.

In context

MeasureXIENCE Everolimus Eluting Coronary Stent SystemProduct code NIQAll MAUDE reports
Reports294128,93226,136,888
Share of that pool—0.2%0%
Classified as death, per 1,000 reports327879
Classified as injury61.2%48.3%36.2%
Classified as malfunction6.1%42.8%62.3%
Filed by the manufacturer100%98.7%94.9%

Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."

Other brands with product code NIQ

BrandReportsLatest 12 monthsClassified as death
Cypher Sirolimus-Eluting Coronary Stent15,051010.3%
Taxus Express2 Paclitaxel-Eluting Coronary Stent System10,256012.5%
Synergy14,271843.5%
Xience V Everolimus Eluting Coronary Stent System6,990911.6%
Promus PREMIER6,1591116.3%
Resolute Onyx Rx5,819888.7%
Promus Element Plus5,238010.2%
Promus Element4,77005.5%
Resolute Integrity Rx4,720707.9%
Taxus Liberte Paclitaxel-Eluting Coronary Stent System4,54305.2%
Xience Xpedition Everolimus Eluting Coronary Stent System4,19904%
Synergy Xd2,8133794%
Promus Everolimus Eluting Coronary Stent System2,734011.3%
Xience Alpine Everolimus Eluting Coronary Stent System2,68103.2%
Endeavor Sprint Rx2,449028.5%

Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."

Questions about XIENCE Everolimus Eluting Coronary Stent System reports

How many FDA reports name XIENCE Everolimus Eluting Coronary Stent System?

294 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 29 in the latest 12 months.

What kinds of events are reported?

injury (61.2%), death (32.7%) and malfunction (6.1%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.

What device problems are coded?

patient-device incompatibility (4.1%), difficult or delayed activation (1.4%), off-label use (1.4%), break (1%) and device damaged by another device (1%). These are FDA's device problem codes as entered on the report.

Who files these reports?

manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.

Do these reports show that XIENCE Everolimus Eluting Coronary Stent System was at fault?

No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."

How do I report a problem with a medical device?

Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.